

BIOGRAPHIES PROVIDED BY ECCO AND NET

CD SATTELITE

Professor Dr. Axel Dignass

Head of the Department of Medicine I and Professor of Medicine and Gastroenterology at the Agaplesion Markus Hospital, Goethe University in Frankfurt, Germany. He graduated in Medicine at the University of Bochum, and later on obtained his PhD from the same university. Since then he has held numerous positions, including Research Fellow at the Massachusetts General Hospital and Harvard Medical School in Boston, USA, and Fellow, Faculty Member and Lecturer at the University of Essen in Germany. Between 1998 and 2005, Axel Dignass was an Attending Physician and Professor at Charité Medical School - Campus Virchow in Berlin, Germany, as well as Director of the IBD Centre at Charité Medical School - Campus Virchow. Axel Dignass is Deputy Chair of the International Organisation for the Study of Inflammatory Bowel Diseases (IOIBD) and Honorary Member of ECCO. He has been Education Officer and Governing Board Member of ECCO and treasurer and governing board member of the German GI society (DGVS). He is past President of United European Gastroenterology (UEG) and has been Congress President of the German GI Society DGVS in 2024, and Endpoint Cluster Chair and member of the nomination committee of IOIBD. His research interests focus on IBD, immunosuppressive and biologic therapy in IBD, anaemia in IBD, AI in IBD, treatment strategies in IBD, molecular mechanisms of intestinal wound healing and cell migration, medical guidelines, and medical education.

Professor Catherine Reenaers

is a senior gastroenterologist at the University hospital of Liege, Belgium. She completed her specialist training in the University hospital of Liège and was a research assistant and research fellow of the Belgian fund of research (FNRS) from 2004 to 2011. Her PhD studied the impact of osteoprotegerin on T cells/dendritic cells interaction and bone remodeling and the role of fibroblasts' apoptosis on fibrosis in IBD. After her PhD, Professor Reenaers was a Senior Clinical and Research Fellow of Dr Travis at the John Radcliffe Hospital, Oxford. She returned to Liège to take a permanent position as IBD specialist where she works with Professor Edouard Louis. She is associated professor and has a charge of course at the university of Liège. She is part of several scientific associations including the scientific committee of BIRD (Belgian Intestinal Research and Developpment group) and the scientific committee of the GETAID (groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif). She was the ECCO (European Crohn and Colitis Organisation) national representative from 2012 till 2020. Pr Reenaers has obtained several scientific awards in Belgian and European conferences and has given many lectures for different scientific societies including outside Belgium. She is involved in intestinal ultrasound and obtained her IBUS certification in 2024.

Professor Stefan Schreiber

Full Professor of Medicine focussed on internal medicine especially gastroenterology. His research interests include molecular genetics and pathophysiology of IBD and the clinical development of new therapies for IBD. He is director of the Clinic of Internal Medicine I (UKSH) and head of the Institute for Clinical Molecular Biology, both at Kiel University, Germany.

Professor Anthony BUISSON

MD, PhD, is a gastroenterologist and researcher in the field of inflammatory bowel disease since 2011. Thanks to his mentor, Prof. Laurent Peyrin-Biroulet, he performed an IBD advanced fellowship in Nancy IBD Unit (France) in 2012 and also worked for a year in the IBD center at the University of Chicago (Illinois, United States) with David T Rubin as mentor. He performed his PhD training (microbiology) in the laboratory of Pr Arlette Darfeuille-Michaud on the interaction between macrophages and adherent and invasive E. coli (AIEC) in Crohn's disease (MC). Since 2017, he is the head of an IBD unit including a research program dedicated to IBD (Clermont-Ferrand University Hospital, France). Between 50 to 70 studies are currently ongoing in his IBD unit including one third as principal investigator. He becomes in 2021, the president of the clinical research department of all the Clermont-Ferrand university hospital. He is an elected member of the GETAID scientific committee since 2012, a member of the REMIND network and has more than 100 original, peer-reviewed publications on IBD. He has been selected (peer-reviewed) as speaker for 35 oral lectures including 15 oral lectures in international meetings (ECCO, DDW, UEGW). Prof. BUISSON and his team are working on non-invasive tools to monitor of IBD activity, especially MRI (transmural healing, Clermont score...) and faecal biomarkers (calprotectin), the prevention of postoperative recurrence in Crohn's disease, patients' acceptability of monitoring tools and treatments, as well as sequencing of biologics or small molecules in IBD (STARTER project). He also strongly collaborates with Prof. Nicolas BARNICH (France) to investigate the role of AIEC in Crohn's disease, especially how targeting the interaction between immune system (macrophages) and the mucosa-associated microbiota to treat patients with IBD.

UC SATTELITE

Professor Ailsa Hart,

BA (Hons), BMBCh, FRCP, PhD St Mark's Hospital and St Mark's Academic Institute London, UK Ailsa Hart is Consultant Gastroenterologist at St Mark's Hospital and Past Dean of St Mark's Hospital Academic Institute. In 2016, she achieved academic promotion at Imperial College London, UK, and is now Professor of Practice, making her among the youngest females to achieve this award at Imperial College. She is also Honorary Skou Professor at the University of Aarhus in Denmark. She studied medicine at Oxford University and was awarded a First-Class Honours Degree. She achieved her PhD with Imperial College London, funded by a Wellcome Trust Fellowship. She has mentored and trained many gastroenterologists, who are now clinical investigators engaged in IBD

research nationally and internationally. Together with many of them, she has published 2 books and over 400 papers, reviews and book chapters and has an h-index of over 80. She was on the Governing Board of the European Crohn's and Colitis Organisation (ECCO) as Scientific Officer, Treasurer and was member of the Clinical Committee of ECCO. She has contributed to the IBD Clinical Research Group Committee for the British Society of Gastroenterology (BSG) and is past Chair of the Gut Microbiota for Health Group of the BSG. She is the UK Patient and Public Involvement Lead for Gastroenterology and is on the Research Committee for the Crohn's and Colitis UK charity. She is a member of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD).

Bram Verstockt,

MD, PhD, is a principal investigator at KU Leuven and a staff member of the IBD team in the Department of Gastroenterology and Hepatology at University Hospitals Leuven (Belgium) since 2021. He provides comprehensive IBD care, leads the multidisciplinary IBD clinic, and drives the implementation of intestinal ultrasound (IUS) within the Leuven IBD unit. He obtained his medical degree from KU Leuven in 2013, completed a PhD in 2019 after research training that included a period at the University of Cambridge (UK), and finalized an additional IUS fellowship in Lüneburg (Germany) in 2021. His research focuses on non-invasive disease monitoring, especially IUS, optimization of imaging tools, and the development of predictive and prognostic biomarkers to support personalized medicine in IBD. He also studies IBD heterogeneity — including perianal disease, fibrostricturing disease, and fatigue — using multi-omics approaches and organoid models. He has held several international leadership roles, including chair of Y-ECCO and chair of the Scientific Committee of IBUS. He currently chairs the Belgian IBD Biobank, serves as Vice President of the European Microscopic Colitis Group, and is a board member of the ECCO Guideline Committee, the Belgian IBD Scientific Committee and the IBUS Collaboration Committee. He is associate editor of the *Journal of Crohn's and Colitis* and an active reviewer for major journals, funding bodies, and conferences. In 2025, he received both the ECCO Young Investigator Award and the UEG Rising Star distinction.

James Lindsay

is the Professor of Inflammatory Bowel Disease at Barts and the London School of Medicine and Dentistry, Queen Mary University of London and a Consultant Gastroenterologist at Barts Health NHS Trust. Along with a full multidisciplinary team he runs the adolescent and adult IBD service at The Royal London Hospital. Professor Lindsay serves on the British Society of Gastroenterology IBD Clinical Trials Steering Group and is Chief Investigator for a series of investigator-led and commercial clinical trials in IBD. In addition, he leads a program of translational mucosal immunology research investigating leukocyte trafficking, monocyte / macrophage differentiation and the control of fibrosis in IBD. He has recently been the Education Officer and a member of the Governing Board of the European Crohn's and Colitis Organisation (ECCO). Before this he served as ECCO e-learning ambassador and chair of the ECCO Education Committee. He has also chaired working groups for the ECCO consensus on the

management of Crohn's disease and ulcerative colitis. He is a member of the International Organisation of IBD (IOIBD)

Elisabeth Schnoy, Germany

Elisabeth Schnoy is a senior physician for internal medicine and gastroenterology at the University Hospital Augsburg in Germany and an assistant professor of gastroenterology at Augsburg University. In January 2025 she was appointed as European Crohn's and Colitis Organisation (ECCO) national representative for Germany. Prof. Schnoy's focus is on chronic IBD and gastrointestinal oncology. She has recent publications in peer-reviewed journals such as *Inflammatory Bowel Diseases*, *Gut*, and *Endoscopy* on subjects including therapeutics for biologic-naïve patients with Crohn's disease (CD) and the use of artificial intelligence (AI) in endoscopy, and she is a review editor for *Gastroenterology*. As head of the study center, Prof. Schnoy is actively involved in clinical trials and translational research. Her experience in bridging clinical data with real-world application will be instrumental in helping participants understand how anti-IL-23 therapy can be effectively integrated into routine care.